Intersect ENT (XENT) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Intersect ENT (XENT) Reports Slight Revenue Miss; Piper Jaffray Cuts Price Target to $23
November 5, 2015 10:00 AM ESTPiper Jaffray maintained an Overweight rating on Intersect ENT (NASDAQ: XENT), and cut the price target to $23.00 (from $30.00), following the company's 3Q earnings report and conference call. XENT reports revenues up 56%, slightly missing consensus of 60%.
Analyst Thomas Gunderson commented, "A slight... More
